Fulminant myocarditis after the second dose of COVID-19 mRNA vaccination

Akihiro Oka; Yuya Sudo; Toru Miyoshi; Masatomo Ozaki; Yuta Kimura; Wataru Takagi; Satoko Ugawa; Tomoaki Okada; Kazumasa Nosaka; Masayuki Doi

doi:10.1002/ccr3.5378

Fulminant myocarditis after the second dose of COVID-19 mRNA vaccination

Clin Case Rep. 2022 Feb 7;10(2):e05378. doi: 10.1002/ccr3.5378. eCollection 2022 Feb.

Authors

Affiliations

¹ Department of Cardiology Kagawa Prefectural Central Hospital Takamatsu City Japan.
² Department of Cardiovascular Medicine Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama City Japan.

Abstract

Myocarditis is an adverse event associated with coronavirus disease 2019 (COVID-19) mRNA vaccination. A 50-year-old man presented with dyspnea and resting chest pain after receiving the second dose of the COVID-19 mRNA vaccine and developed cardiogenic shock. Fulminant myocarditis was diagnosed by endomyocardial biopsy and treated with intravenous corticosteroids.

Keywords: COVID‐19 mRNA vaccination; fulminant myocarditis; steroid pulse therapy.

Publication types

Case Reports